• Medicure’s first-half 2026 performance was driven by rising ZYPITAMAG sales, supported by Marley Drug’s direct-to-consumer cash-pay channel.
• Pharmacy operations expanded with Gateway Medical Pharmacy and West Olympia Pharmacy, positioning the group to pursue synergies and support ZYPITAMAG growth.
• AGGRASTAT maintained significant US market share, supported by Medicure’s exclusive 3.75 mg bolus vial format.
• Pipeline progress continued with an ongoing Phase 3 pivotal trial for MC-1 in PNPO deficiency.
• Medicure highlighted early-stage work on MC-008, a new chemical entity program, with clinical targets not yet disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-007759), on August 19, 2026, and is solely responsible for the information contained therein.